Orveko posted this: Re: McMagyar Post# 65583
"Agreed that there is much misinformation here and elsewhere. As always, please validate my posts and others' against your own DD. Regarding IP protection, A2-73 is currently protected by one patent related to its use as a combination therapy for the treatment of melanoma. This patent is valid through 2030 or so, but *only* as a combination therapy for the treatment of melanoma. Alzheimer's is not covered in the claims."
However, Orveko also recently pointed out that we should have more patent news soon.
IPman also posted this in May 2016:
ipulator_man Member Level Tuesday, 05/03/16 02:09:22 PM
Re: neiu post# 61503
Post # of 74155
A normal timeline. The application was filed 10/19/2015. It is a combo therapy like the PLUS app. A WIPO patent is preferable to a US only patent.
Here is my updated list:
-------------------------------
Anavex IP Portfolio:
GRANTED PATENT:
U.S. Pat. No. 8,673,931
“Bicyclic Heterocyclic Spiro Compounds” (ANAVEX 3-71, previously AF710B, composition)
U.S. Pat. No. 9,180,106
"Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity" (ANAVEX 2-73 Method of use, cancer)
PATENT PENDING:
U.S. Pat. App. No.13/940,352
“Anavex2-73 and Certain Anticholinesterase Inhibitors Composition and Method for Neuroprotection”
U.S. Pub. No. 20140296211 (ANAVEX 2-73 Method of use, Alzheimer's Disease)
WIPO Pat App No.WO2016064711
U.S. Prov. Pat. App. No.62/065,833
“A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy”
Provisional (ANAVEX 2-73 Method of use, epilepsy)
UNPUBLISHED:
U.S. Pat. App. No. 13/777,471
“Sigma-Receptor Ligands with Anti-Apoptotic and/or Pro-Apoptotic Properties Over Cellular Biochemical Mechanisms, with Neuroprotective, Anti-Cancer, Anti-Metastatic and Anti-(Chronic) Inflammatory Action”
Not yet published
Identical to parent U.S. Pat App. No. 12/522,761 / U.S. Pub. No. 20100069484 (ANAVEX 2-73 Composition & Method of use, cancer?)
-------------------------------
The company could PR the preclinical epilepsy results along with this associated patent app this summer.
Thank you Dr Thomas!
§
Learn about the Portfolio that Adapts
